RohteshSMehtaMD

Oncology • Houston, TX

Hematologic Oncology, Hospice & Palliative

Physician

Join to view full profile

Dr. Mehta is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mehta's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2011 - 2014
UPMC Medical EducationFellowship, Hospice and Palliative Medicine, 2009 - 2010
Mercy Catholic Medical CenterResidency, Internal Medicine, 2006 - 2009
Government Medical College PatialaClass of 2003

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2016 - 2026
WA State Medical License 2022 - 2025
OK State Medical License 2020 - 2021
MN State Medical License 2015 - 2017
PA State Medical License 2006 - 2014
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant Start of enrollment: 2021 Apr 08
Active, not recruiting
Phase 1

Publications & Presentations

PubMed

SOHO State of the Art Updates and Next Questions | Current Status and Future Directions of Donor Selection.
Rohtesh S Mehta
Clinical Lymphoma, Myeloma & Leukemia. 2024-12-01
1 citations
Decreasing chronic graft-versus-host disease rates in all populations.
Paul A Carpenter, Ted A Gooley, Julie Boiko, Catherine J Lee, Lauri M Burroughs
Blood Advances. 2024-11-26
Corrigendum to 'Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation' [Transplan...
Mansour Alkhunaizi, Badar Patel, Luis Bueno, Neel Bhan, Tahreem Ahmed
Transplantation and Cellular Therapy. 2024-11-17

Journal Articles

Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction Drugs
Krina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature

Abstracts/Posters

Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation
Rohtesh S. Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Do...
Rohtesh S. Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients
Rohtesh S. Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
Rohtesh Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study
Rohtesh S. Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Ver...
Rohtesh S. Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receivi...
Rohtesh S. Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation
Rohtesh Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis
Rohtesh S. Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Re...
Rohtesh S. Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantat...
Rohtesh S. Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS
Rohtesh Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression
Rohtesh S. Mehta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation after Double Cord Blood Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Guest Editorial: Advances in Immunotherapy for Hematological MalignanciesFebruary 9th, 2018

Professional Memberships

American Society of Hematology - ASH
Member